Tag: Dr. Ebrahim Delpassand

Satya Das MD Grand Rounds June 21 2022

News and Notes from the Carcinoid Cancer Foundation, July 2022

July 13, 2022
Neuroendocrine Cancer Specialist Dr. Satya Das Presents Grand Rounds at Vanderbilt University

Have you wondered what it’s like to attend Grand Rounds dedicated to neuroendocrine cancer?  NET expert Satya (Nanu) Das, MD, MSCI, Assistant Professor…

READ MORE
NCCN Guidelines Neuroendocrine and Adrenal Tumors 2

Detectnet (copper Cu 64 dotatate injection) Now Included in NCCN Guidelines® for Neuroendocrine Tumors

May 10, 2021

The newest FDA-approved PET imaging agent for neuroendocrine tumors — DetectnetTM (copper Cu 64 Dotate injection) — is now included in the National Comprehensive Cancer Network ® (NCCN) Clinical Practice Guidelines in Oncology – Neuroendocrine

READ MORE
CCF FB LIVE Ebhrahim S. Delpassand MD April8

Dr. Ebrahim Delpassand to be Featured Guest for CCF’s Luncheon with the Experts

April 5, 2021

Ebrahim S. Delpassand, MD, FACNM, Chairman and Medical Director at Excel Diagnostics & Nuclear Oncology Center in Houston, Texas and founder, Chairman of the Board, and CEO of Radiomedix in Houston, will be the featured guest for Luncheon with the…

READ MORE
thomas odorisio md theranostics congress march 2015

15 Videos from the 3rd Theranostics World Congress

May 14, 2015

The 3rd Theranostics World Congress featured a patient education day on Saturday, March 14, made possible with support from the Carcinoid Cancer Foundation and the Caring for Carcinoid Foundation. The NorCal CarciNET Community provided funding to…

READ MORE
ebrahim delpassand md

First U.S. Center to Enroll Patients in International, Multicenter Clinical Trial of Lu-177 Octreotate

November 20, 2012

Excel Diagnostics and Nuclear Oncology Center in Houston, Texas, is the first center in the United States to start recruiting patients in a multicenter randomized clinical trial of Lu-177 Octreotate in patients with progressive midgut carcinoid. …

READ MORE
ebrahim s delpassand md facnm

FDA Approves Amendment for PRRT Clinical Trial in Texas

August 2, 2012

BREAKING NEWS:  The Food and Drug Administration (FDA) has just approved the RadioIsotope Therapy of America (RITA) Foundation’s amendment to the Investigational New Drug (IND) protocol for intra-hepatic artery administration of Lu-177 Octreotate

READ MORE
unicorn foundation 2011

Worldwide NET Cancer Awareness Day Update: Events from Australia to Europe to North America

November 7, 2011

Go around the globe for the second Worldwide NET Cancer Awareness Day (WNCAD) on November 10, 2011. Throughout that day, videos featuring NET events and experts will air on www.netcancerday.org  as the sun travels west, from Australia to Europe to North…

READ MORE
Richard R.P. Warner, MD2

Pancreatic Neuroendocrine Tumors: A Rare Cancer

August 26, 2011

From your next door neighbor to Steve Jobs, co-founder of Apple who just announced that he is stepping down as CEO of the company, pancreatic neuroendocrine tumors (pNETs) affect less than 1 person in 100,000 in the United States.  This rare cancer is often…

READ MORE
CCAN logo

9 Conferences for the Carcinoid and Neuroendocrine Tumor Community

July 19, 2011

If you are a carcinoid or NET cancer survivor, caregiver, family member or medical professional you can learn about what’s happening now and what’s new in carcinoid/NETs treatments, clinical trials, research, and more from specialists…

READ MORE
glucomedix1

RadioMedix $2.8 Million Grant from Texas Emerging Technology Fund to Result in New Products that Benefit Carcinoid and Neuroendocrine Cancer Patients

March 23, 2011

Two innovative products that will enable users to generate and label PET radiotracers on-site at a significantly reduced cost will be developed by RadioMedix, Inc. with a $2.8 million grant from the Texas Emerging Technology Fund.  According to Ebrahim

READ MORE